欧洲 · 股市与财经 · Proactive Investors
Lilly's triple GLP-1 combination raises the stakes for Novo Nordisk
Eli Lilly's experimental obesity drug combination has delivered weight loss of up to 23.3% in a mid-stage trial, adding to pressure on rival Novo Nordisk, according to Citi. The…
在 Proactive Investors 阅读全文 登录后可收藏MediaNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.proactiveinvestors.co.uk)




